Harmonix Fund
VC Fund
Palm Springs, United States
Harmonix Fund is a VC fund in Palm Springs focused on Health Care and Biotechnology. Venture capital fund helping entrepreneurs launch exponential organizations generally with an impact or sustainability element.Passionate about creating positive impact at scale for humanity and the planet.Particular interest in human optimization, healthcare, and strategic interest in automotive and manufacturing technology.Specialties:HealthTech, Healthcare, DeepTech, impact, Startups, Early Stage, seed, Series A, VC, Angel investor, AutoTech, ManufacturingTech, Robotics, IoT, AgTech, connecting the dots.
- Total investments:
- 48
- Last investment:
- Lead investor:
- 2%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Harmonix Fund invests in
Health CareBiotechnologyArtificial IntelligenceSoftwareMedical
Stages Harmonix Fund invests in
SeedSeries AFunding RoundSeries BVenture - Series Unknown
Countries Harmonix Fund invests in
United StatesCanadaGermanyHong Kong
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anthony DeFeo
|
|||
Cofield Mundi
|
|||
Krish Ramadurai
|
|||
Maximilian Winter
|
Investment Focus
Industry
- Health Care 18 (38%)
- Biotechnology 18 (38%)
- Artificial Intelligence 11 (23%)
- Software 8 (17%)
- Medical 6 (13%)
Stage
- Seed 14 (29%)
- Series A 10 (21%)
- Funding Round 7 (15%)
- Series B 5 (10%)
- Venture - Series Unknown 4 (8%)
Country
- United States 34 (71%)
- Canada 2 (4%)
- Germany 1 (2%)
- Hong Kong 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anthony DeFeo
Managing Director of Marketing and Investor Relations
|
Managing Director of Marketing and Investor Relations | Total investments: 0 | Find email | |
|
Cofield Mundi
Partner
|
Partner | Total investments: 0 | Find email | |
Katya Kohen
Partnership and Network Lead
|
Partnership and Network Lead | Total investments: 4 | Find email | |
|
Krish Ramadurai
Partner
|
Partner | Total investments: 10 | Find email | |
|
Maximilian Winter
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SentiAR
|
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $8.5M / Series B / Apr 11, 2023 | |
ATLAS Space Operations
|
ATLAS Space Operations is the Satellite Communications as a Service Getting Your Data, Faster | $26M / Series B / Aug 25, 2022 | |
Caresyntax
|
Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $130M / Series C / Sep 16, 2021 | |
Sorcero
|
Sorcero provides an AI-powered intelligence platform tailored for life sciences teams. It enables medical affairs, safety, scientific communications, and medtech groups to extract meaningful insights from unstructured and structured biomedical data. Through its Instant Insights Engine and agentic AI framework, users can ask conversational questionsand quickly receive medically validated answers linked to their source material. Sorcero also offers tools for literature monitoring, safety signal detection, and converting complex science into clear, plain-language summaries. The platform supports compliant workflows by providing auditability, AI guardrails, and access controls to manage insights securely. | $10M / Series A / Sep 16, 2021 | |
Attivare Therapeutics
|
Attivare Therapeutics develops biomaterial vaccines to facilitate multiple applications. | $6M / Seed / Aug 17, 2021 | |
xCures
|
The convergence of genomics, precision medicine, and AI have created an unprecedented moment in the world of oncology. But the drug-centric way in which treatments are developed and the haphazard way in which knowledge about those treatments is captured and delivered to the point of care does not serve patients well. xCures is changing that, withan AI-based precision oncology platform that tightly integrates cancer research and care.The xCures platform runs a perpetual trial that captures Real World Evidence (RWE) to continuously learn from all patients, on all treatments, all the time. It coordinates treatment recommendations across all patients and institutions to match patients with the treatments that work. And it packages RWE for use by stakeholders across oncology, slashing the time and cost of drug development and saving lives. | $12.7M / Series A / Jun 23, 2021 | |
Strateos
|
Strateos automates chemistry, biology, and tissue analysis into closed-loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, they enable pharmaceutical partners to more rapidly and efficientlydiscover new drug candidates.Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development.By expressing life science methods as data, infrastructure virtualization will become possible. "Science-as-a-Service" will power the next generation of discovery, driven by huge efficiencies of both time and money.Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology.Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs.They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists. | $56.1M / Series B / Jun 08, 2021 | |
Sana Health
|
Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD.SOSV, Founders Fund, Noetic Fund,Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures. | Venture - Series Unknown / May 26, 2021 | |
Scribe Biosciences
|
Our fundamental technology, Printed Droplet Microfluidics (PDM), is a flexible and reconfigurable fluid handling system to perform picoliter-scale manipulations. By leveraging fluorescence-activated microfluidic droplet sorting and a specialized substrate, PDM enables the flexible and deterministic handling of single cells and fluid aliquots atextremely high throughputs. | $2.4M / Venture - Series Unknown / May 12, 2021 | |
|
Scribe Biosciences
|
Our fundamental technology, Printed Droplet Microfluidics (PDM), is a flexible and reconfigurable fluid handling system to perform picoliter-scale manipulations. By leveraging fluorescence-activated microfluidic droplet sorting and a specialized substrate, PDM enables the flexible and deterministic handling of single cells and fluid aliquots atextremely high throughputs. | $500K / Angel / May 12, 2021 | |
| See all 48 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Harmonix Fund invest in?
Harmonix Fund invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 48 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Harmonix Fund?
Public channels for Harmonix Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Harmonix Fund?
The team at Harmonix Fund includes Anthony DeFeo (Managing Director of Marketing and Investor Relations), Cofield Mundi (Partner) and Katya Kohen (Partnership and Network Lead). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
